EAMS opinion issued for dupilumab in the treatment of children with severe atopic dermatitis

Dupilumab can be used in the treatment of children aged six to 11 years with severe atopic dermatitis that is not controlled by medicines applied as creams or ointments to the skin.

Join OnMedica and benefit from:

  • Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
  • High-quality, evidence-based content developed by expert editors and clinicians
  • Articles, quizzes, videos, visual summaries and more
  • Regulatory alerts and round-up of medical journals
  • New content added daily, so you know you’re always up to date

Existing members Sign in